9 Recruiting Recurrent Diffuse Large B-Cell Lymphoma Phase 1 Clinical Trials
Active phase 1 studies for recurrent diffuse large b-cell lymphoma enrolling across the USA. Verify eligibility and contact site coordinators.
All Recurrent Diffuse Large B-Cell Lymphoma studiesPhase 1 Studies for Recurrent Diffuse Large B-Cell Lymphoma
Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma
📍 City of Hope Medical Center — Duarte, California
View Study & Checklist ➔Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
📍 University of Chicago Comprehensive Cancer Center — Chicago, Illinois
View Study & Checklist ➔Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma
📍 City of Hope Comprehensive Cancer Center — Duarte, California
View Study & Checklist ➔NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma
📍 Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington
View Study & Checklist ➔Lymphodepletion With Low Dose Total Body Irradiation Before Standard of Care Tisagenlecleucel for the Treatment of Relapsed and Recurrent Large B-cell Lymphoma
📍 Ohio State University Comprehensive Cancer Center — Columbus, Ohio
View Study & Checklist ➔Evaluation of Bridging Radiation Therapy Before CAR T-Cell Infusion for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma
📍 City of Hope Medical Center — Duarte, California
View Study & Checklist ➔Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
📍 University of Minnesota/Masonic Cancer Center — Minneapolis, Minnesota
View Study & Checklist ➔Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
📍 University of California Davis Comprehensive Cancer Center — Sacramento, California
View Study & Checklist ➔ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma
📍 Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington
View Study & Checklist ➔